Drug Type Monoclonal antibody |
Synonyms 重组人源化抗IL17A单克隆抗体 (上海三生国健), 608, SSGJ-608 |
Target |
Mechanism IL-17A inhibitors(Interleukin 17A inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization- |
Active Organization |
Inactive Organization- |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Plaque psoriasis | NDA/BLA | CN | 19 Nov 2024 | |
Non-radiographic axial spondyloarthritis | Phase 2 | CN | 18 Mar 2024 | |
Ankylosing Spondylitis | Phase 2 | CN | 27 Feb 2024 | |
Autoimmune Diseases | Phase 2 | CN | 30 Jan 2022 |
NCT05536726 (NEWS) Manual | Phase 3 | - | 608:160 mg W0+80 mg Q2W+80mg Q4W | jxqgkowrrw(fzaopkhggy) = hpajznhknu mtsrqsofto (opsoskfemq ) Met View more | Positive | 02 Aug 2024 | |
608:160 mg Q4W+160mg Q8W | jxqgkowrrw(fzaopkhggy) = iiewtmygwl mtsrqsofto (opsoskfemq ) Met View more |